From the wall street transcript
as you can tell Hopeful ......
they have been in discussions with the FDA .....
for some time now .....
TWST: Are there any milestones that you can set out for the next year or
two?
Mr. Gabriel: Our milestones have always been the same. They haven't
changed from the first day I came onboard. The goal is to make the
company profitable as soon as possible, and we're pursuing that by
developing products that we can get out into the market. Our new
DNAWITNESS test kit is just an example. We continue to build our
database. We have a 2,500 photo database and we collect samples. We're
building our product portfolios to make our products attractive to the
customers in genealogy as well as in forensics, and we will continue to
do that. Pharmacogenomics is a longer haul, but it certainly offers a
much greater point of return when a product is approved and is accepted
by the market. So we look at it in a three-step fashion. We look at our
consumer products market, building our continued consumer base, and we
have probably sold, oh, I don't know, 11,000 or 12,000 samples, or kits
into that market, and our long-term goal is to have, quite literally,
millions of those. So we will be a very unique company in that we will
have analyzed, literally, millions of DNA samples on a blind basis '
blind samples. We know nothing about the individuals; we just get a DNA
sample, and we report on it back to them. We also think there's a
tremendous opportunity in forensics. In the investigation of cold cases
-' and there's a backlog of hundreds, if not hundreds of thousands of
such cases ' our technology can be used to help categorize those cases.
Certainly categorizing DNA samples is important for the Innocence
Project. If a crime scene sample shows that the suspect is Caucasian and
the individual who's incarcerated is African-American, obviously, you
move his DNA to the top of the pile and you do the match and you free
him. So there's plenty of opportunity in those two markets for growth.
It's steady and consistent growth. It will, however, not be the bell
ringer. The real bell ringer for this technology has always been in the
pharmaceutical area, really matching the patient with the doctor and
with the therapy through 'Theranostics.' That's what this technology can
do. It can actually put the doctor and patient back in control of the
pharmaceuticals that are being administered for the disease that's being
treated. We can do this one step at a time, one drug at a time. We'll
just proceed down that path and have an open dialog with the FDA, the
NIH and move our technology forward. In addition, we're looking at
licensing opportunities for therapeutics as well ' in other words,
talking to people about drugs that we can bring in. We want to run
clinical trials of drugs along with our technology, and instead of
having 40% or 60% efficacy we could have up to 95% efficacy, which means
longer product life. That's a novel concept, and an important one.
Especially when patents expire, the question always is, how you keep
generics out. Well, how you keep generics out is that you have a product
that is 95% efficacious. That builds brand loyalty, and people don't
want to change. Aspirin has been around for a couple of hundred years,
and everybody knows Bayer aspirin; or Tylenol, anyone can make Tylenol,
but no one thinks of acetaminophen, people think of Tylenol. That's
brand loyalty. It's something that's been around in the pharmaceutical
industry itself, and you do that by making a product that, when you take
it, the result is there. You take Bayer aspirin, you know what you get;
you take Tylenol, you know what you get. So if you have a disease and
you have a drug that treats the disease, the doctor knows that it's an
efficacious drug, and if you match the patient to the drug and it works,
then that's what's going to happen. That's how scrips are generated.
TWST: Thank you. (TJM)
I GUESS THATS WHAT I HAVE - BRAND LOYALTY --- GEO
AI
